Obinutuzumab
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Obinutuzumab |
| DrugBank ID | DB08935 |
| Brand Names (EU) | Gazyvaro |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.47% |
Approved Indication (EMA)
Chronic lymphocytic leukaemia (CLL) Gazyvaro in combination with chlorambucil is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) and with comorbidities making them unsuitable for full-dose fludarabine based therapy. Follicular Lymphoma (FL) Gazyvaro in combination with chemotherapy, followed by Gazyvaro maintenance therapy in patients achieving a response, is indicated for the treatment of patients with previo
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | acute lymphoblastic/lymphocytic leukemia | 99.47% | DL |
| 2 | chronic lymphocytic leukemia/small lymphocytic lymphoma with immunoglobulin heavy chain variable-region gene somatic hypermutation | 99.21% | DL |
| 3 | pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma | 99.21% | DL |
| 4 | follicular lymphoma | 99.18% | DL |
| 5 | Richter syndrome | 99.17% | DL |
| 6 | mantle cell lymphoma | 98.75% | DL |
| 7 | metastatic neoplasm | 98.51% | DL |
| 8 | malignant spiradenoma | 98.47% | DL |
| 9 | neoplasm of mature B-cells | 98.08% | DL |
| 10 | small intestinal Burkitt lymphoma | 97.84% | DL |
| 11 | Langerhans cell histiocytosis | 97.81% | DL |
| 12 | thyroid gland mucosa-associated lymphoid tissue lymphoma | 97.76% | DL |
| 13 | small intestinal mucosa-associated lymphoid tissue lymphoma | 97.75% | DL |
| 14 | chronic lymphocytic leukemia/small lymphocytic lymphoma | 97.73% | DL |
| 15 | breast mucosa-associated lymphoid tissue lymphoma | 97.72% | DL |
| 16 | tonsillar lymphoma | 97.67% | DL |
| 17 | B-cell neoplasm | 97.19% | DL |
| 18 | follicular lymphoma, susceptibility to, 1 | 97.09% | DL |
| 19 | histiocytic and dendritic cell neoplasm | 96.62% | DL |
| 20 | childhood carcinoid tumor | 96.55% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.